跳轉至內容
Merck
全部照片(3)

重要文件

A9010

Sigma-Aldrich

Ethyl arachidate

≥99%

同義詞:

Ethyl eicosanoate, Ethyl ester of eicosanoic acid, Arachidic acid ethyl ester

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C22H44O2
CAS號碼:
分子量::
340.58
MDL號碼:
分類程式碼代碼:
12352211
PubChem物質ID:
NACRES:
NA.25

生物源

synthetic (organic)

品質等級

化驗

≥99%

形狀

solid

官能基

ester

脂質類型

omega FAs

運輸包裝

ambient

儲存溫度

−20°C

SMILES 字串

CCCCCCCCCCCCCCCCCCCC(=O)OCC

InChI

1S/C22H44O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h3-21H2,1-2H3

InChI 密鑰

YBKSMWBLSBAFBQ-UHFFFAOYSA-N

應用


  • Optimizing the Design of Blood-Brain Barrier-Penetrating Polymer-Lipid-Hybrid Nanoparticles for Delivering Anticancer Drugs to Glioblastoma.: This study explores the development of nanoparticles that can cross the blood-brain barrier to deliver anticancer drugs directly to glioblastoma, utilizing ethyl arachidate in their composition to enhance drug encapsulation and targeting (Ahmed et al., 2021).

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Samara R Alves Rico et al.
Nanoscale, 9(30), 10701-10714 (2017-07-06)
A unique class of diruthenium(ii,iii) metallodrugs containing non-steroidal anti-inflammatory drug (NSAID), Ru
Samara Rodrigues Alves et al.
Journal of inorganic biochemistry, 205, 110984-110984 (2020-01-14)
Novel formulations of diruthenium(II,III)-NSAID (NSAID, non-steroidal anti-inflammatory drug) metallodrugs encapsulated into biocompatible terpolymer-lipid nanoparticles (TPLNs) to target glioblastoma cancer were developed. The nanoformulations of Ibuprofenate (RuIbp) and Naproxenate (RuNpx) metallodrugs were synthesized and characterized. The procedure rationally designed to avoid
Tian Zhang et al.
Advanced healthcare materials, 8(18), e1900543-e1900543 (2019-07-28)
Patients with brain metastases of triple negative breast cancer (TNBC) have a poor prognosis owing to the lack of targeted therapies, the aggressive nature of TNBC, and the presence of the blood-brain barrier (BBB) that blocks penetration of most drugs.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務